Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Neovascularization stimulated by VEGF occurs in several important clinical contexts, including myocardial ischemia, retinal disease, and tumor growth.
|
8756616 |
1996 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
This report summarizes a phase I clinical experience with a gene-therapy strategy that used an E1(-)E3(-) adenovirus (Ad) gene-transfer vector expressing human vascular endothelial growth factor (VEGF) 121 cDNA (Ad(GV)VEGF121.10) to induce therapeutic angiogenesis in the myocardium of individuals with clinically significant coronary artery disease.
|
10430759 |
1999 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recent experiments performed in this same porcine model of myocardial ischemia have shown that direct intramyocardial gene transfer of naked plasmid DNA encoding VEGF (phVEGF(165), the identical plasmid used in our previous animal and human clinical trials) can be safely and successfully achieved through a minimally invasive chest wall incision.
|
10426872 |
1999 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We correlated the VEGF response to hypoxia in the monocytes harvested from patients with coronary artery disease with the presence of collaterals visualized during routine angiography.
|
10430770 |
1999 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We initiated a phase 1 clinical study to determine the safety and bioactivity of direct myocardial gene transfer of vascular endothelial growth factor (VEGF) as sole therapy for patients with symptomatic myocardial ischemia.
|
9860779 |
1999 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease.
|
10509970 |
1999 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this brief review, the role of a prime angiogenic candidate, namely vascular endothelial growth factor (VEGF) and its homologues, in physiological and pathological angiogenesis will be discussed with particular attention to myocardial ischemia and heart failure.
|
10865845 |
2000 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recently, the efficacy of therapeutic angiogenesis using VEGF (vascular endothelial growth factor) gene transfer has been reported in human patients with critical limb ischemia and myocardial ischemia.
|
11426585 |
2000 |
Coronary Arteriosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In the dog heart, an important model for studies of myocardial ischemia and angiogenesis, the expression of VEGF remains to be established.
|
11195786 |
2000 |
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
3 years) with chronic stable angina due to angiographically documented coronary artery disease, all of whom had failed conventional therapy (drugs, PTCA, and/or CABG), were treated with direct myocardial injection of phVEGF(165) via a minithoracotomy.
|
10961959 |
2000 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Several clinical trials based on intramyocardial injection of VEGF DNA in patients with otherwise inoperable coronary artery disease and intractable angina pectoris have recently been completed.
|
14728030 |
2001 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease: anesthetic management and results.
|
11133594 |
2001 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The central role of vascular endothelial growth factor (VEGF) in angiogenesis in health and disease makes it attractive both as a therapeutic target for anti-angiogenic drugs and as a pro-angiogenic cytokine for the treatment of ischaemic heart disease.
|
11166270 |
2001 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results of application of vascular endothelial growth factor (VEGF) GT strategies for therapeutic angiogenesis in critical limb and myocardial ischemia in pilot clinical trials was reviewed.
|
11773594 |
2001 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Direct intramyocardial administration of VEGF(165)-DNA and VEGF(167)-DNA may result occasionally in an enhancement of collateral vascularization in regions with diffuse peripheral coronary artery disease not surgically amenable.
|
11717016 |
2001 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Currently, about 200 patients have been treated with intramyocardial VEGF gene therapy for peripheral occlusive artery disease or for myocardial ischemia.
|
12582471 |
2002 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
CTD_human |
Gene therapy of coronary artery disease with phvegf165--early outcome.
|
14668888 |
2003 |
Coronary Arteriosclerosis
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Gene therapy of coronary artery disease with phvegf165--early outcome.
|
14668888 |
2003 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Catheter-based intracoronary vascular endothelial growth factor (VEGF) gene transfer is a potential treatment for coronary heart disease.
|
12742981 |
2003 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, more research including large scaled clinical trials is needed before deciding whether the vascular endothelial growth factor therapy either as a gene or a recombinant slow-release protein formulation therapy can be offered to patients with severe coronary artery disease, which cannot be treated with conventional revascularization.
|
12762479 |
2003 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
PET for evaluation of differential myocardial perfusion dynamics after VEGF gene therapy and laser therapy in end-stage coronary artery disease.
|
15347709 |
2004 |
Coronary Arteriosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Because hypoxia-inducible factor (HIF)-1alpha is a transcriptional activator of vascular endothelial growth factor (VEGF) and is critical for initiating angiogenic responses to hypoxia, we investigated the expression of HIF-1alpha and VEGF in specimens of human heart tissue to elucidate the molecular responses to myocardial ischemia in diabetic patients during unstable angina.
|
15331549 |
2004 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mobilization of endothelial progenitor cells with cytokines potentiates VEGF-2 gene therapy for myocardial ischemia and enhances bone marrow cell incorporation into ischemic myocardium.
|
15337699 |
2004 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings suggest a crucial role of VEGF-A in the development of coronary artery disease.
|
15754021 |
2005 |
Coronary Arteriosclerosis
|
0.400 |
Therapeutic
|
disease |
CTD_human |
VEGF polymorphisms and severity of atherosclerosis.
|
15937083 |
2005 |